Oxford BioMedica PLC (OXBDF)

[georgejjl]

Oxford BioMedica, a UK biotech, is also forecast to see strong benefits from an eventual FDA approval for CTL019. It has created the LentiVector platform — a gene delivery system using a virus that is introduced into the body which is needed to administer CAR-T.

Jefferies is forecasting “an important sustainable revenue stream” of about £65m to £75m in annual income for Oxford BioMedica if the drug receives the green light.

John Dawson, chief executive, said: “We are obviously delighted with the decision and look forward to the potential approval. As the manufacturer of the lentiviral vector inside CTL019 this is important for us financially given the royalty stream, and great news for patients.”

https://www.ft.com/content/36540334-6739-11e7-8526-7b38dcaef614

Good luck and GOD bless,

George